Transcript rheumatology

Management of
Rheumatoid arthritis,
Osteoarthritis & Gout
Dr. Eoin Casey MD FRCPI, FRCP
Background Reading

Davidson’s Principles & Practice of Medicine, 50th
Anniversary Ed, 2002

Musculoskeletal disorders, Ch 20: pg 957-1047

Clinical Assessment of the Musculoskeletal System
(handbook) Arthritis and Rheumatism Council UK
http://www.arc.org.uk/about_arth/opubs/6321/6321.pdf
General Assessment






History
Clinical examination
Functional anatomy
Physiology
Investigations
Major manifestations of
musculoskeletal disease
Symptoms & Signs








Joint pain
Stiffness
Swelling
Inflammation
Skin changes
Muscle changes
Deformity
Non-specific systemic symptoms
(weight↓; appetite↓; energy ↓; concentration ↓; mood ↓)
Osteoarthritis
Aetiology is unknown
Aims of management

Educate the patient

Control pain

Optimise function

Beneficially modify the disease process
“It is much more important to know
what sort of a patient has a
disease than what sort of a
disease a patient has.”
William Osler 1849-1919
Management of OA

Patient’s personality

Attitude

Holistic factors
- activities of daily living
- co-morbid disease

Availability, cost & logistics of evidence-based
intervention
Patient education

Randomized controlled trials have
shown that education results in
substantial improvement and
prolonged benefit
Management of OA

Exercise
- aerobic fitness
- local strengthening exercises

Weight reduction

Simple analgesia
- eg Paracetamol 1g 4-6 hrly

Non-steroidal anti-inflammatory drugs
-
(NSAIDS)
NSAIDS



>40 NSAIDS available in Ireland
Top most prescribed drugs in the world
In favour of their use are
- effectiveness
- lack of toxicity
- affordability


Variable individual tolerance and response
Non-responders to one agent may improve
with another
NSAIDS

Mechanism of Action
- ↓ prostaglandin levels
- inhibit cyclooxygenase (COX)
Cyclo-oxygenase isoforms

COX I
- housekeeping enzyme
- expressed in gastric mucosa,
platelets & kidney

COX II
- inflammatory enzyme
- expressed in various tissues
largely at sites of inflammation
The COX II controversy
Selective COX II inhibitors
Gastric side effects of NSAIDS

GIT toxicity - up to 30%

Aetiological factor in 30% gastric ulcers

10% of RA/OA patients hospitalised
annually for NSAID associated bleeding

Endoscopic evidence of ulceration in
20% of NSAID users even in absence of
symptoms

2000 deaths per annum in UK
Risk factors for NSAID gastritis

Age > 60 years

Past history of PUD

Past history of adverse effects with NSAIDS

Steroid use

High doses

Multiple NSAIDS

Specific NSAIDS eg Indomethacin, Azapropazone

↓risk - Proton pump inhibitors; Ranitidine

Cyto-protection with Mesoprostil
NSAIDS side effects

Older people are at greatest risk for
- renal
- cardiovascular
- GIT toxicity
Other treatment modalities

Nutri-pharmaceuticals
- Glucosamine
- Chondroitin Sulphate

Topical agents

Physiotherapy

Occupational therapy
Rheumatoid arthritis
Aetiology is unknown
Approach to management

Holistic approach to assessment

Education is as important as medications

NSAIDS

Corticosteroids

Disease modifying agents (slow acting)
Steroids in Rheumatoid Arthritis

Glucocorticoids in low doses <7.5mg
daily are very effective to bridge the
gap of the latent period before disease
modifying drugs work

Local intra-articular steroid injections
Disease modifying agents









Hydroxychloroquine
Salazopyrine
Penicillamine
Gold
Methotrexate
Azathioprine
Luflunomide
Cyclophosphamide, Cyclosporine
Anti TNF agents
eg Adalimumab (Humira), Etanercept (Embrel), Infliximab
Non-drug treatments

Physiotherapy

Physical treatments

Surgery

Coping strategies
Gout
Gout

Crystal deposition

Negatively bi-refringent sodium monouric
crystals in joints, bursa, tendons and kidney

Not always associated with hyperuricaemia
Stages of Gout

1. Acute Gout

2. Inter critical periods

3. Chronic tophaceous Gout
Treatment of acute attack

One of the most painful conditions
known

NSAIDS

Colchicine (main s/e diarrhoea)

Steroids
Long term management

Uricosuric agents
-
Allopurinol 100mg od increasing to 300mg od
MOA: Xanthine oxidase inhibitor
2-3 weeks after acute attack
initiation may precipitate an acute attack
Gout in Older People

Association with thiazide diuretics

Increased toxicity to Allopurinol